名媛直播

Greg Laub

Greg Laub

Authors >

Greg Laub

Greg Laub joined 名媛直播 in 2005 as Production Manager and led the launch of the video department in 2007. He currently leads the video and podcast production teams. Greg's passion to craft a story began as a writer, with stops as Managing Editor at USOpen.org, Creative Director at Bernard Hodes Advertising, and copywriter at AOL Time Warner. He's even had one of his screenplays produced -- he believes it was beloved by all seven people who saw it. Greg lives in New Jersey with his wife, two kids and two dogs.

Connect:

email image

Latest from Greg Laub

Quads, Frailty, and the Future: Evolving Frontline Strategies in Multiple Myeloma

Experts at ASH debate quadruplet therapy, dexamethasone modulation, and novel approaches

Health of Myeloma Patient's Marriage Tied to Recovery After Transplant

Study links strong relationships to better physical and emotional outcomes in myeloma care

Optimizing Sequencing of BCMA-Directed Therapies in Myeloma

Longer gaps between anti-BCMA agents associated with improved response rates, study finds

Mosunetuzumab in Follicular Lymphoma: Durable Responses and Manageable Safety

Experts talk about long-term data and the importance of infection prophylaxis

Advances in ALL at ASH Meeting Include New Blinatumomab Data and More

Researchers also examined MRD to guide treatment decisions, and other personalized approaches

Experts Debate AQUILA Trial Findings in Smoldering Multiple Myeloma

Phase III trial sparks discussion on defining and managing high-risk smoldering myeloma

Benefits of Drug Combo in Myeloma Maintenance Shown in Relevant Subgroups

MRD-negativity rates improved across subgroups, supporting daratumumab-lenalidomide combination

Pain, Fatigue Benefits May Give Resistance Training a Leg Up in Multiple Myeloma

Structured exercise improves fatigue and pain but requires long-term patient commitment

Masking Policies Show Clear Impact on Hospital-Onset Respiratory Infections

Study links lifting and reintroducing masking policies to infection rate changes

Fostamatinib Fails to Improve Outcomes in Hypoxemic COVID Patients

Drug did not increase oxygen-free days versus placebo in randomized study

1

鈥�